Stimulant use disorder affects millions of Americans, yet many misconceptions remain about how it develops, how it is diagnosed, and how it can be treated. Although there are no FDA-approved medications currently available specifically for stimulant use disorder, emerging research shows several medications—including dextroamphetamine, bupropion, naltrexone, and mirtazapine—have shown promise in reducing stimulant use. In this Ask the Expert video, Dr. William Stoops, Professo

According to the latest Monitoring the Future (MTF) Panel Study from the University of Michigan, young and midlife adults are reporting sharp increases in several emerging substance use behaviors, including nicotine pouches, cannabis, vaping, and psychedelics. For 50 years, MTF surveys nationally representative samples of 8th, 10th, and 12th-graders, tracking trends in youth substance use and following a subset of 12th-grade participants into adulthood. Today, the MTF Panel

The Substance Use and Mental Health Services Administration (SAMHSA) announced updated guidelines that expand the incentive cap for...

“Cross-sensitization” refers to extreme responses to one substance after earlier use of a different drug.

No known medical treatments exist for overdose, dependence, craving, relapse, or to reverse all of the effects of methamphetamine use.